27 November 2024 - - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC on 3-4 April 2025.

The agenda currently has 14 items. Applications of note include:

1708.1 - Hepatitis delta virus RNA PCR testing to determine eligibility for PBS subsidised bulevirtide for treatment of patients with hepatitis D virus infection

1732.1 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates

1762 - Amendment to HER-2 MBS item to allow for trastuzumab deruxtecan for the treatment of patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma

1767 – Immunohistochemistry testing for Claudin 18 expression in patients with gastric or gastro-oesophageal junction cancers, to determine eligibility for PBS subsidised zolbetuximab treatment

1769 – Human leukocyte antigen testing for hypersensitivity to carbamazepine and oxcarbazepine

1779 – Testing of tumour tissue to detect FGFR2 fusions or rearrangements in people with cholangiocarcinoma, to determine eligibility for treatment with PBS subsidised futibatinib

1782 – Genetic testing to detect oestrogen receptor 1 (ESR1) variants in patients with oestrogen receptor positive, HER2 negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised elacestrant

1791 – Dinutuximab beta for primary relapse and refractory high-risk neuroblastoma

Read MSAC agenda